Filter
1758
Text search:
meta-analysis
Featured
201
241
Language
1406
138
113
109
48
44
24
19
7
3
2
2
1
1
1
1
1
1
1
1
Document type
738
408
396
71
62
42
20
9
6
2
1
Countries
93
56
43
37
33
31
28
23
22
21
20
17
16
16
16
15
14
13
11
11
11
10
10
10
9
9
8
8
8
8
8
8
8
8
8
7
7
7
6
6
6
6
6
6
5
5
5
5
5
5
5
4
4
4
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
366
106
89
70
49
45
27
20
20
18
13
13
13
12
11
11
11
10
10
10
9
9
9
8
7
7
7
6
6
6
6
6
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Publication Years
734
959
64
1
Category
422
209
117
111
47
12
9
Toolboxes
319
284
176
103
96
78
60
47
42
41
20
18
17
13
11
9
9
8
6
5
5
4
3
3
3
Групповая интерперсональная терапия (ипт) при депрессии
recommended
Gerald L. Klerman, Myrna M. Weissman et al.
WHO, Columbia University in the city of New York
(2018)
C_WHO
Данное руководство по применению групповой интерперсональной терапии (групповой ИПТ) в лечении депрессии дополняет собой mental health Gap Action Programme Intervention Guide (mhGAP-IG) («Рук
...
оводство mhGAP по принятию мер в отношении психических и неврологических расстройств») (WHO, 2016). Цель настоящего руководства заключается в предоставлении подробных инструкций по проведению групповой ИПТ, которая в соответствии с mhGAP является одним из первоочередных методов психологического лечения этого расстройства.
more
20 February 2013
Update on 2004 Background Paper (Written by Saloni Tanna)
Priority Medicines for Europe and the World "A Public Health Approach to Innovation"
Interventions for carers of people with dementia
World Health Organization
(2012)
C_WHO
Q9: For carers of people with dementia, do interventions (psychoeducational, cognitive-behavioural therapy counseling/case management, general support, training of caregivers, multi-component interventions and miscellaneous interventions) when compared to placebo/comparator, produce benefits/harm in
...
the specified outcomes?
more
Role of antidepressants in people with dementia and associated depression
World Health Organization
(2012)
C_WHO
Q4: For people with dementia with associated depression, do antidepressants when compared to placebo/comparator produce benefits/harm in the specified outcomes?
Cognitive and psychosocial interventions
World Health Organization
(2012)
C_WHO
Q5: For people with dementia, which cognitive/psychosocial interventions (such as cognitive stimulation, cognitive rehabilitation, reality orientation, reminiscence therapy) when compared to placebo/comparator produce benefits/harm in the specified outcomes?
Conventional and and atypical antipsychotics & antidepressant (trazodone) for behavioural and psychological symptoms in people with dementia
World Health Organization
(2012)
C_WHO
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?
EPI 2: First-line anti-epileptic medication for management of acute convulsive seizures, when intravenous access is available [2015]
mhGAP; WHO
(2015)
C_WHO
SCOPING QUESTION: In adults with acute convulsive seizures, where intravenous access is available, which first-line anti- epileptic medication should be used to abort seizures when compared to comparator?
[Updated 2015]
Scoping Question: In adults with acute convulsive seizures in first-level care or in the community (when no IV access is available), which antiepileptic medications produce benefits and/or harm when compared to comparator?
EPI 3: Anti-epileptic medications for management of established status epilepticus [Updated 2015]
mhGAP; WHO
(2015)
C_WHO
SCOPING QUESTION: In adults with established status epilepticus (i.e., seizures persisting after the first-line treatment with benzodiazepines [or benzodiazepines-resistant status epilepticus]), which anti-epileptic medications are associated with cessation of seizures and reduced adverse effects)?
...
more
Psychosocial interventions for the management of cannabis dependence [Updated 2015]
mhGAP; WHO
(2015)
C_WHO
SCOPING QUESTION: Which psychosocial interventions are effective in the management of cannabis dependence?
SCOPING QUESTION:Which psychosocial interventions are effective in the treatment of psychostimulant dependence for adults and young people?
Executive Summary - Chapter 3 Pharmacological Treatment
R. Ali
ATLAS on substance use (2010)— Resources for the prevention and treatment of substance use disorder; WHO
(2019)
C_WHO
ATLAS on substance use (2010)— Resources for the prevention and treatment of substance use disorder
Accessed: 14.03.2019
Цель: изучение технологий виртуальной реальности в реабилитации больных с церебральным инсультом
и их влияния на постинсультные аффективные нарушения.
http://www.ssmj
...
.ru/system/files/2014_04-01_824-827.pdf
more
The new guidelines provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings. These guidelines update the recommendations for managing hyperglycaemia in the WHO Package of Essential NCD I
...
nterventions (WHO PEN) for primary care in low-resources settings, reviewing several newer oral agents as second- and third-line treatment: dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter 2 inhibitors and thiazolidinediones. The guidelines also present recommendations on the selection of type of insulin (analogue versus human insulin) for adults with type 1 and type 2 diabetes.
more
Addressing comorbidity between mental disorders and major noncommunicable diseases (Russian Version)
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB,
...
including longer and shorter regimens, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care.
more
Role of sterile injection equipment and outreach programmes for injecting drug users
World Health Organization
(2012)
C_WHO
Q 6. Does the provision of sterile injection equipment to injecting drug users reduce injecting related harm? Is advice on ways to reduce drug related harm safe and effective, using an outreach model of service delivery?
Treatment of psychostimulant dependence
World Health Organization
(2012)
C_WHO
Q3: Are pharmacotherapies safe and effective for the treatment of psychostimulant dependence (maintenance or relapse prevention) in non-specialized settings?
Ежегодно табак убивает более 7 миллионов человек (1), то есть ежедневно в результате употребления табака или воздействия вторичного табачного дыма (ВТД) умирает бол
...
е 19 000 человек. Большинство таких случаев смерти происходят в странах с низким и средним уровнем доходов, население которых подвергается активному маркетингу табачной промышленности.
more
This publication seeks to describe the best treatments and practices based on the scientific evidence available at the time of writing as evaluated by the authors and may change as a result of new research. Readers need to apply this knowledge to patients in accordance with the guidelines and laws o
...
f their country of practice. Some medications may not be available in some countries and readers should consult the specific drug information since not all the unwanted effects of medications are mentioned.
more
